louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01384110: Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human
Official title: Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hyperglycemia
Keywords: Amylase
Glucosidase
Glycemic response
Sucrose
Seaweed
Lead sponsor: innoVactiv Inc.
Sponsor class: INDUSTRY
First posted: 2011-06-28
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The primary endpoint of this trial will be to evaluate if a single administration in human of a lemon ice tea containing 500 mg of a polyphenol-rich algal powder is able to reduce postprandial glycemia and insulinemia.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteer aged 18 to 60
* BMI between 20 and 30
* Non-smoking
* Using valid contraceptive method (women of childbearing age)

Exclusion Criteria:

* Iodine allergy, or allergy to components of the test product or placebo or standard meal
* Diabetes
* Use of dietary supplements for duration of study
* History of gastro-intestinal affections, anemia, major surgeries or surgeries of the stomach or digestive tract

Primary outcomes:
measure: Significant reduction in postprandial glycemia
timeFrame: Immediately after product administration (single use)
measure: Significant reduction in postprandial insulinemia
timeFrame: Immediately after product administration (single use)
Secondary outcomes:
measure: Frequency and severity of Adverse Events as a Measure of Safety and Tolerability
timeFrame: First administration up to 7 days after last administration
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)
Study officials:
affiliation: Institut des nutraceutiques et des aliments fonctionnels
name: Patrick Couture, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04682210: Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection
Official title: A Phase III, Randomized, Open-lable, Multi Center Study of Sintilimab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Curative Hepatic Resection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: HCC
Adjuvant Therapy
Immunotherapy
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2020-12-23
Enrollment: 246
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open label, multi-center, randomized, controlled phase III study, to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after radical resection

Detailed description: There is no stardard adjuvant treatment for HCC. This study is to to evaluate the efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in HCC patients who are at high risk of recurrence after radical resection.

Eligibility criteria: Inclusion Criteria:

* Patients with a first diagnosis of HCC who have undergone a curative resection
* Radiologic evidence of disease free ≥4 weeks after complete surgical resection
* Full recovery from surgical resection or post-operative transarterial chemoembolization before randomization
* Randomization needs to occur within 12 weeks of the date of surgical resection
* High risk for HCC recurrence as protocol defined
* Child-Pugh Score, Class A
* ECOG performance status 0 or 1
* No prior systemic anticancer therapy for HCC
* Adequate hematologic and organ function

Exclusion Criteria:

* Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
* Evidence of residual, recurrent, or metastatic disease at randomization
* History of hepatic encephalopathy or organ transplantation
* Patients who are in the waiting list for liver transplantation
* Patients with Vp4 portal vein thrombosis
* Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or other immunotherapy
* Pregnant or lactating women

Primary outcomes:
measure: Recurrence-free Survival (RFS)
timeFrame: up to 36 months after randomization
Secondary outcomes:
measure: Overall Survival (OS）
timeFrame: up to 48 months after randomization
measure: RFS Rate at 12 and 24 months
timeFrame: at 12 and 24 months after randomization
measure: OS Rate at 24 and 36 Months
timeFrame: at 24 and 36 months after randomization
measure: TTR(time to recurrence)
timeFrame: up to 36 months after randomization
measure: Adverse Events (AEs)
timeFrame: up to 48 months after randomization
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
References:
Clinical trial NCT00801710: CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study
Official title: CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Disease
Coronary Artery Chronic Total Occlusion
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
Collaborators: name: BridgePoint Medical
First posted: 2008-12-03
Enrollment: 42
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to determine if the BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire) can facilitate safe and effective placement of a guidewire in the true lumen of coronary vessels distal to a chronic total occlusion (CTO).

The hypothesis is that the BridgePoint Medical System can do this without an increase in major complications.


Eligibility criteria: Inclusion Criteria:

* Suitable for coronary intervention
* de novo or restenotic CTO at least 3 months old, in proximal or mid coronary artery segment, 3.0-5.0 mm in diameter
* Mild/moderate proximal vessel tortuosity
* Mild/moderate lesion angulation
* Mild/moderate calcification
* Satisfactory distal vessel visualization
* Mild/moderate side branch interference
* 19 years old
* BMI\<40
* LVEF\>20%
* Signed informed consent

Exclusion Criteria:

* Extensive dissection from guidewire manipulation
* SVG or in-stent CTO
* Aorto-ostial CTO
* Unable to take aspirin, Clopidogrel, or Ticlopidine
* Thrombus/vessel filling defects
* Severe cerebrovascular disease/stroke within 1 month
* Intervention within 2 weeks
* Renal insufficiency
* GI bleeding
* Active infection
* Life expectancy \<2 years
* Significant anemia
* Uncontrolled hypertension
* Severe electrolyte imbalance
* Anaphylaxis to contrast
* NYHA class IV
* Unstable angina requiring intervention
* MI within 2 weeks
* Uncontrolled diabetes
* Participating in another protocol
* Unwilling/unable to comply with protocol
* Angina/ischemia caused by target vessel

Primary outcomes:
measure: CTO Crossing Rate
timeFrame: Peri-procedural
Secondary outcomes:
measure: Major Adverse Cardiac Events (MACE)
timeFrame: 30 days
measure: Perforation rate
timeFrame: Peri-procedural
measure: Acute myocardial infarction (AMI)
timeFrame: Peri-procedural
Other outcomes:
Locations:
city: Bad Soden
country: Germany
facility: Main Taunus Hospital
city: Darmstadt
country: Germany
facility: Klinikum Darmstadt
city: Frankfurt
country: Germany
facility: CardioVascular Center Frankfurt, St. Katharinen Hospital
city: Hamburg
country: Germany
facility: Universitäres Herz- und Gefässzentrum Hamburg
Study officials:
affiliation: CardioVascular Center Frankfurt, St. Katharinen Hospital
name: Horst Sievert, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04267510: Clinical and Molecular Aspects of Early Osteoarthritis
Official title: Clinical and Molecular Aspects of Early Osteoarthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Early Osteoarthritis
Keywords: genetic sequencing
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-02-13
Enrollment: 65
Sex: ALL
Minimum age (years): 7
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with early osteoarthritis who have undergone genetic sequencing

Brief summary: The etiology of osteoarthritis is varied, ranging from multifactorial, environmental to monogenic. In individuals in whom osteoarthritis appears earlier than in the general population, it is called early osteoarthritis. To our knowledge, there are no large-scale genetic studies on people with early osteoarthritis. The investigators therefore sought to study the causes of monogenic osteoarthritis in people suffering from early non-syndromic osteoarthritis.

Material and method From 2013 to 2019, experts in constitutional bone disease sent patients with non-syndromic early osteoarthritis for genetic analysis to our center of competence for constitutional bone diseases. The sequencing of a panel of genes was carried out by NGS.


Eligibility criteria: Inclusion Criteria:

- Patients with early osteoarthritis who have undergone genetic sequencing

Exclusion Criteria:

- Patients refusing to participate in research

Primary outcomes:
measure: identification of genetic mutation
timeFrame: 1 day
measure: number of genetic mutation
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: UH Montpellier
Study officials:
affiliation: Department of Medical Genetics
name: David GENEVIEVE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00834210: Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acne Vulgaris
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2009-02-03
Enrollment: 171
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris


Eligibility criteria: Inclusion Criteria:

* Facial acne vulgaris characterized by the following: 30-100 facial inflammatory lesions; and 25-100 facial non-inflammatory lesions; stable disease, non-rapidly regressing facial acne vulgaris; and, 3 or more nodules and/or cysts (diameter of 1cm or greater). Female subjects of childbearing potential must have a negative pregnancy test at baseline and practice reliable method of contraception throughout the study

Exclusion Criteria:

* Non-compliance with washout period; history of clinically significant anemia or hemolysis; skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris; allergy or sensitivity to any component of the test medications

Primary outcomes:
measure: Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: Change From Baseline in Investigator Global Assessment at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Overall Disease Severity at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Non-Inflammatory Lesion Counts (Open and Closed Comedones) at Week 12
timeFrame: Baseline, Week 12
Other outcomes:
Locations:
city: Fremont
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03240510: Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience
Official title: Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Male Breast Cancer
Keywords: Breast cancer
Male
Lead sponsor: Salah Azaïz Cancer Institute
Sponsor class: OTHER
First posted: 2017-08-07
Enrollment: 150
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective part: All men with histologically proven invasive breast carcinoma diagnosed between 2004 and 2013.

Prospective part: All men with histologically proven invasive breast carcinoma diagnosed between 2014 and 2017.

Brief summary: The goal of this study is to evaluate the Salah Azaïz Cancer Institute male breast cancer patients population over a period of 14 years.

Goal of the retrospective part: to gather clinicopathologic data and follow-up outcomes of male breast cancer patients diagnosed and/or treated at Salah Azaïz Cancer Institute from 2004 to 2013.

Goal of the prospective part: to create a registry of male patients with breast cancer for a period of 48 months (from 2014 to 2017).


Eligibility criteria: Inclusion Criteria:

Histological diagnosis of male breast cancer

Primary outcomes:
measure: Clinical outcomes
timeFrame: Through study completion, an average of 4 year
measure: Clinico-biological characteristics of the disease
timeFrame: Through study completion, an average of 4 year
Secondary outcomes:
Other outcomes:
Locations:
city: Tunis
country: Tunisia
facility: Salah Azaïz Cancer Institute
Study officials:
affiliation: Salah Azaïz Cancer Institute
name: Syrine Abdeljaoued, PhD
role: STUDY_CHAIR
affiliation: Salah Azaïz Cancer Institute
name: Ilhem Bettaieb, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Salah Azaïz Cancer Institute
name: Amor Gamoudi, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05802810: The Mass Balance Study of [14C]JT001
Official title: The Mass Balance Study of [14C]JT001 in Chinese Healthy Adult Male Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Sponsor GmbH
First posted: 2023-04-07
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single Group
Primary purpose: TREATMENT

Brief summary: This study is a single center, single dose, non-randomized, open design clinical study.By quantitative analysis of the biological samples of subjects after oral administration of \[14C\]JT001, the data of human radioactive excretion rate and the main excretion pathway will be obtained. The main metabolites ,metabolic pathways and elimination pathways of JT001 will be identified.


Eligibility criteria: Inclusion Criteria:

1. Healthy adult males
2. Age: 18-45 years old
3. Body weight: Body mass index (BMI) is between 19.0 and 26.0 kg/m2 (including boundary values), and the body weight of the subject is not less than 50.0 kg;
4. Voluntarily sign informed consent;
5. Subjects were able to complete the trail according to protocol.

Exclusion Criteria:

1. Physical examination, vital signs, routine laboratory examination, imaging examination abnormal and clinically significant
2. The electrocardiogram was abnormal and was considered clinically significant by the investigators, or has a history of organic heart disease
3. Has hepatitis B (HBV) or hepatitis C (HCV) or HIV antibody and syphilis antibody positive;
4. Any drug that inhibits or induces the drug transporters P-gp and BCRP has been used within 30 days prior to the screening period
5. Any conditions that may affect drug absorption.
6. Previous antineoplastic therapy meets washout requirements.
7. Hemorrhoids or perianal disease with regular/ongoing blood in the stool, irritable bowel syndrome, inflammatory bowel disease
8. Habitual constipation or diarrhea.
9. Significant radioactive exposure within 1 year.

Primary outcomes:
measure: Total radioactive recovery
timeFrame: 1 month
measure: cumulative excretion rate of total radioactive material in fecal matter
timeFrame: 1 month
measure: Peak concentration（Cmax）
timeFrame: 1 month
measure: time to peak（Tmax）
timeFrame: 1 month
measure: elimination half life（t1/2）
timeFrame: 1 month
measure: Major metabolites in human plasma, urine, and feces by liquid chromatography-mass spectrometry (LC-MS/MS)
timeFrame: 1 month
Secondary outcomes:
measure: Adverse events (AEs)
timeFrame: 2 month
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
References:
Clinical trial NCT04797910: Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Official title: Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Portal Hypertension
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2021-03-15
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with hepatitis B cirrhosis

Brief summary: Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between the wedged hepatic venous pressure (WHVP) and the free hepatic vein pressure (FHVP)- has been the criterion standard to determine portal pressure. Antiviral therapy may decrease HVPG which needs to be verified.


Eligibility criteria: Inclusion Criteria:

* Patients with viral cirrhosis were diagnosed;
* Age 18-80 years;
* Need and willing to accept measure HVPG;
* First HVPG measurement of more than 5 mmHg;
* Signed Informed Consent

Exclusion Criteria:

* Patients with viral cirrhosis have been treated with antiviral therapy and have achieved virological response;
* Ready to accept or have accepted a TIPS procedure;
* Splenic embolization was performed;
* Inaccurate measurement of HVPG due to combined hepatic venous shunt;
* Complicated with alcoholic liver disease, autoimmune liver disease or other types of liver disease;
* Complicated with liver cancer or other organ malignancy;
* Combined with severe cardiopulmonary disease affects survival;
* Complicated with severe renal insufficiency;
* Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis;
* Women who are planning to become pregnant or who are pregnant or breastfeeding.

Primary outcomes:
measure: HVPG changed and reached the response standard
timeFrame: one year
Secondary outcomes:
measure: Antiviral therapy achieved a virological response
timeFrame: one year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01199510: Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dry Eye
Cataract Surgery
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2010-09-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness of FID 112903 (SYSTANE ULTRA® Lubricating Drops) plus standard of care to standard of care alone, in subjects with a history of intermittent eye irritation or dryness related to environmental factors and scheduled for routine cataract surgery.


Eligibility criteria: Inclusion Criteria:

* Patients must be at least 18 years of age
* Patients must be seeking routine cataract extraction with monofocal intraocular lens implantation

Exclusion Criteria:

* Patients for whom both eyes do not meet all inclusion criteria and either eye meets any exclusion criteria.
* Patients cannot have a history of hypersensitivity to any component of FID 112903.
* Patients cannot have previous intraocular or corneal surgery or any planned within 30 days.
* Patients cannot use any ocular medications other than test article and standard of care post-op medications in past 14 days or during study.
* Patients cannot be on chronic systemic corticosteroid or other immunosuppressive therapy.
* Patients cannot have a history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative Intraocular pressure \>25 millimeters mercury in either eye.
* Patients cannot have a history and/or current evidence of the following: clinically significant corneal scarring, blepharitis or macular pathology in either eye, Herpes zoster or Herpes simplex keratitis.

Primary outcomes:
measure: Ocular Comfort
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: http://www.escrs.org/abstracts/details.asp?confid=9&sessid=372&type=free&paperid=14295
Clinical trial NCT06383910: The Effect Of Square Stepping Exercise Training On Cognitive Functions And Quality Of Life In Geriatric Individuals
Official title: The Effect Of Square Stepping Exercise Training On Cognitive Functions And Quality Of Life In Geriatric Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: geriatric
cognitive functions
square stepping exercise
quality of life
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 56
Sex: ALL
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was designed to investigate the effects of Square-Stepping Exercise Training on cognitive functions and quality of life in geriatric individuals. The volunteer participants in the study were randomly divided into two groups: a square-stepping exercise group and a control group.

In the study, participants in the exercise training groups received square stepping exercises three days a week for six weeks, while those in the control group did not undergo any training. Both groups were assessed before and six weeks after the training period.

The investigators used several assessment tools including Hodkinson's Mental Test, Montreal Cognitive Assessment, Stroop Test, Trail Making Test, and the Turkish World Health Organization Quality-of-Life Scale.


Eligibility criteria: Inclusion Criteria:

* Individuals aged between 65-75 years old,
* Able to walk independently,
* Hodkinson Mental Test score ≥ 8,
* Without any neurological or lower extremity-affecting diseases,
* Healthy geriatric individuals who agreed to participate in the study were included.

Exclusion Criteria:

* Using 3 or more medications,
* Hodkinson Mental Test score \<8,
* Currently participating in any exercise/rehabilitation program,
* Geriatric individuals with a history of lower extremity surgery

Primary outcomes:
measure: Change on Cognitive Functions from Base on the Montreal Cognitive Assessment In 6 Weeks
timeFrame: Baseline and 6 weeks
measure: Change on Cognitive Functions from Base on the Stroop Test In 6 Weeks
timeFrame: Baseline and 6 weeks
measure: Change on Cognitive Functions from Base on the Trail Making Test In 6 Weeks
timeFrame: Baseline and 6 weeks
measure: Change on Quality of Live from Base on the World Health Organization Quality-of-Life Scale Turkish version In 6 Weeks
timeFrame: Baseline and 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
Study officials:
affiliation: PhD student
name: Yelda Soykurt
role: PRINCIPAL_INVESTIGATOR
References: